Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Clinical trial NCT02453282 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02453282
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-21
- Primary completion
- 2018-10-04
- Enrollment
- 1118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.